help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lima, L.
Right arrow Articles by Devesa, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lima, L.
Right arrow Articles by Devesa, J.

Journal of Clinical Endocrinology & Metabolism, Vol 76, 439-444, Copyright © 1993 by Endocrine Society

ARTICLES

Glucocorticoids may inhibit growth hormone release by enhancing beta- adrenergic responsiveness in hypothalamic somatostatin neurons

L Lima, V Arce, MJ Diaz, JA Tresguerres and J Devesa
Department of Physiology, Faculty of Medicine, University of Santiago de Compostela, Spain.

The aim of this study was to investigate the mechanisms by which glucocorticoids inhibit GH secretion in man. In 10 normal volunteers subjects we compared the pattern of GHRH-induced GH release to that elicited by similar challenge given 60 min after a pretreatment with drugs affecting adrenergic and muscarinic cholinergic neurotransmission, both in basal situations and after having induced hypercortisolism. In a first study (P), synthetic GHRH [GRF-(1-29); 1 microgram/kg, i.v.] was administered 60 min after giving placebo. In other experiments, the administration of propranolol (PRO; 40 mg, orally), or clonidine (CLO; 0.300 mg, orally), or pyridostigmine (PD; 120 mg, orally) was followed by GHRH administration 60 min later. These experiments were repeated after giving a nocturnal dose of dexamethasone (DEX; 8 mg, orally at 2300 h). The administration of DEX significantly (P < 0.05) blunted the GH response to GHRH (peaks: 10.7 +/- 3.9 vs. 20.3 +/- 5.5 micrograms/L; DEX vs. P study, respectively). Conversely, either beta-adrenergic blockade (PRO), or alpha 2- adrenergic agonism (CLO), or the enhancement of muscarinic cholinergic tone (PD) significantly increased the GH response to GHRH (peaks: 43 +/- 4.6, 55.6 +/- 5.6 and 51.2 +/- 7, micrograms/L; PRO, CLO, and PD, respectively; P < 0.01 vs. P study). After nocturnal DEX administration, both PRO and CLO, but not PD, were able to reverse the inhibitory effect of DEX on GHRH-elicited GH release (peaks: 39 +/- 5.5, 25.9 +/- 3.9 and 12.9 +/- 3.1, micrograms/L; DEX + PRO, DEX + CLO, and DEX + PD, respectively). However, whereas the potentiating effect of PRO on GHRH-elicited GH release was still observed under hypercortisolism, it was lacking for both CLO and PD when these drugs were given in this situation. These data suggest that the inhibitory effect of glucocorticoid excess on GH release is due to increased hypothalamic somatostatin secretion which appears to be dependent on DEX-induced enhanced beta-adrenergic responsiveness. Moreover, the data further support a major role of hypothalamic alpha 2-adrenergic and beta-adrenergic activities in GH neuroregulation in man.


This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
E. E. Muller, V. Locatelli, and D. Cocchi
Neuroendocrine Control of Growth Hormone Secretion
Physiol Rev, April 1, 1999; 79(2): 511 - 607.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society